ClinicalTrials.gg
RecruitingNCT07685015Updated Jul 6, 2026

The Impact of Myo-Inositol on Glycemic Control and Oxidative Stress in Gestational Diabetes Mellitus

An interventional study of Myo-inositol 2 g + Folic acid 200 µg and Folic acid 200 µg in Gestational Diabetes Mellitus (GDM), sponsored by Medical University of Vienna. Recruiting at 2 sites in Austria. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes, Gestational with a site in Austria — 4 open to participants now, 5 under way, none of them phase 3. Diabetes, Gestational · Austria.

Started
2026
the only one that year
No phase
5 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
7 of 11
Medical University of Vienna

Among the 11 studies in Diabetes, Gestational with a site in Austria, this one is the only one that started in 2026, is one of 5 with no phase, and was the 9th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

4 of the 11 studies in Diabetes, Gestational with a site in Austria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes, Gestational with a site in Austria, or all of them as a file.
02

Study summary

The purpose of this clinical study is to investigate the potential effects of myo-inositol supplementation on changes in glycemic control parameters, oxidative stress, inflammatory biomarkers, psychometric markers, and body composition in participants with gestational diabetes mellitus (GDM).

The study duration is 3 to 3.5 months, depending on the time of GDM diagnosis. Before the active phase begins, there is a 10-day observation period during which participants' blood glucose levels are monitored using a continuous glucose monitoring device. In the subsequent 12-14-week study phase, participants will receive a supplement based on random group assignment. They will be allocated either to an intervention group (myo-inositol + folic acid) or a control group (folic acid). Both supplements will be taken until delivery.

The intervention group supplement contains 4 g myo-inositol and 400 μg folic acid (BIOGENA GmbH, Salzburg) and is to be taken twice daily with water - three capsules per meal. The control group supplement contains only 400 μg folic acid (BIOGENA GmbH, Salzburg) and is also taken twice daily, one capsule per meal. As this is a pilot study, both participants and study personnel will be aware of group assignments.

Blood glucose measurements will be repeated mid-study (around the 33rd week of pregnancy) and at the end (37th week of pregnancy) using glucose sensors. To improve the evaluation of glucose measurements, participants will keep dietary logs during these periods.

Three study visits are planned, during which the following assessments will be conducted. To determine the primary outcome, "time in range (TIR)" (time spent within the target glucose range), three glucose sensor measurements will be performed. At each visit, blood samples will be taken to analyze glycemic control parameters (hemoglobin A1c (HbA1c), fasting glucose, fasting insulin, Homeostasis Model Assessment (HOMA-IR), insulin dosage), oxidative stress markers (total antioxidant capacity, malondialdehyde levels), and inflammatory markers (interleukin-6 (IL-6), C-reactive protein (CRP)). Anthropometric measurements (weight gain, blood pressure, pulse) and body composition (Bioelectrical Impedance Analysis) will also be performed.

Additionally, maternal and fetal birth outcomes will be recorded, including cesarean section rates, fetal gestational weight, preterm birth rates, and neonatal hypoglycemia occurrence. To assess participants' well-being and physical activity, questionnaires will be distributed at the beginning and end of the study.

03

Conditions studied

  • Gestational Diabetes Mellitus (GDM)

Keywords

  • Gestational Diabetes Mellitus
  • GDM
  • Myo-Inositol
  • Continous Glucose Monitoring
  • CGM
  • Oxidative Stress
  • Inflammation
  • Glycemic Control
  • Inositol
  • MYO
  • MI
  • Pregnancy
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • GDM diagnosis
  • at least one of the HAPO-Study criteria: 2h-oGTT → >153 mg/dl, 1h-oGGT → >180 mg/dl, fasting plasma glucose > 92 mg/dl
  • age between 18-45
  • single pregnancy

Exclusion criteria

Exclusion Criteria:

  • T2DM
  • T1DM
  • Maturity Onset Diabetes of the Young (MODY)
  • Latent Diabetes in Adults (LADA)
  • pre pregnancy >35
  • oral antidiabetic drugs
  • pre-existing renal disease
  • heart disease and other chronic medical disorders
  • allergies to any ingredients contained in the dietary supplements
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    1. Intervention group (nutrition therapy + myo-inositol + folic acid)

    Women who maintain their blood glucose levels within the normal range through nutritional therapy and receive the investigational supplement myo-inositol plus folic acid.

    Dietary Supplement: Myo-inositol 2 g + Folic acid 200 µg · Behavioral: Nutrition therapy

  • Experimental
    2. Intervention group (insulin therapy + myo-inositol + folic acid)

    Women who are already receiving insulin therapy to maintain their blood glucose levels within the normal range and receive the investigational supplement myo-inositol plus folic acid.

    Dietary Supplement: Myo-inositol 2 g + Folic acid 200 µg · Drug: Insulin therapy

  • Active comparator
    3. Control group (nutrition therapy + folic acid)

    Women who maintain their blood glucose levels within the normal range through nutritional therapy and receive the supplement folic acid.

    Dietary Supplement: Folic acid 200 µg · Behavioral: Nutrition therapy

  • Active comparator
    4. Control group (inuslin therapy + folic acid)

    Women who are already receiving insulin therapy to maintain their blood glucose levels within the normal range and receive the supplement folic acid.

    Dietary Supplement: Folic acid 200 µg · Drug: Insulin therapy

Interventions

  • Dietary supplementMyo-inositol 2 g + Folic acid 200 µg

    Drug page: InositolStudies of InositolInositol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This dietary supplement contains 2 g of myo-inositol and 200 µg folic acid per capsule. It should be taken twice a day (à 3 capsules) with fluid intake and a meal.

  • Dietary supplementFolic AcidStudies of Folic AcidFolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This dietary supplement contains 200 μg of folic acid per capsule and should also be taken twice a day (à 1 capsule) with adequate fluid intake and a main meal.

  • DrugInsulin therapy

    Women with GDM who maintain their blood glucose levels with insulin therapy.

  • BehavioralNutrition therapy

    Women with GDM who maintain their blood sugar levels with nutritional therapy.

06

What researchers measure

Primary outcomes

  1. Time in Range

    Time in Range \[%\] measured with continous glucose monitoring

    Time frame: 10 days at baseline (24.-28. gestational week), 10 days into gestational week 33, 10 days into gestational week 36/37

Secondary outcomes

  1. Fasting glucose

    fasting glucose \[mg/dl\] concentration

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  2. Fasting insulin

    fasting insulin \[μIU/mL\] concentration

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  3. HOMA-IR

    HOMA-IR calculated as fasting insulin level (micro-units per milliliter) multiplied by the fasting blood glucose level (milligrams per deciliter), dividing the result by 405

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  4. HbA1c

    HbA1c \[%\] concentration

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  5. Insulin doses

    insulin units \[IU\]

    Time frame: from day 1 until delivery

  6. Pre Pregnancy BMI

    weight \[kg\]/height \[m\]\^2

    Time frame: before pregnancy

  7. Height in meters

    height \[m\]

    Time frame: at baseline

  8. Weight in kilograms

    weight \[kg\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  9. Blood Pressure

    blood pressure \[mmHg\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  10. C-Section (maternal and fetal outcomes)

    C-Section yes or no

    Time frame: at delivery

  11. Hypoglycemia of the child (maternal and fetal outcomes)

    glucose values of the child \[mg/dl\]

    Time frame: at delivery

  12. Preterm birth (maternal and fetal outcomes)

    delivery before 37. gestational week yes or no

    Time frame: at delivery

  13. Gestational weight of the child (maternal and fetal outcomes)

    gestational weight of the child \[kg\]

    Time frame: at delivery

  14. Oxidative stress parameter

    total antioxidative capacity \[µmol/l\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  15. Oxidative stress parameter

    Malondialdehy status \[µmol/l\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  16. Inflammatory parameter

    C-reactive protein \[mg/dl\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  17. Inflammatory parameter

    interleucin-6 \[pg/ml\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  18. Psychometric parameter

    Questionnaire: Pregnancy-related Anxiety score * minimum score: 10 * maximum score: 50

    Time frame: 24.-28. gestational week, 37. gestational week

  19. Psychometric parameter

    Questionnaire: Postnatal-Depression score * total possible score: 0-30 * higher scores: more depressive symptoms

    Time frame: 24.-28. gestational week, 37. gestational week

  20. Psychometric parameter

    Questionnaire: Perceived Stress score * minimum raw score: 20 * maximum raw score: 80

    Time frame: 24.-28. gestational week, 37. gestational week

  21. Physical Activity parameter

    Questionnaire: Physical Activity score \[MET\] \- average daily energy expenditure by calculating the metabolic equivalents (METs) for each activity

    Time frame: 24.-28. gestational week, 37. gestational week

  22. Nutritional log

    Food diary for 10 days

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  23. Bioelectrical Impedance Analysis (BIA)

    fat mass \[kg\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  24. Bioelectrical Impedance Analysis (BIA)

    total body water \[%\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  25. Bioelectrical Impedance Analysis (BIA)

    muscle mass \[kg\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  26. Bioelectrical Impedance Analysis (BIA)

    fat free mass \[%\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  27. Bioelectrical Impedance Analysis (BIA)

    body cell mass \[%\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

  28. Bioelectrical Impedance Analysis (BIA)

    extracellular mass \[%\]

    Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week

07

Study locations

2 of 2 sites recruiting
  • Allgemeines Krankenhaus (AKH) Vienna, Medical University of Vienna
    Vienna, State of Vienna 1090, Austria
    Recruiting
  • Medical University of Vienna
    Vienna, State of Vienna 1090, Austria
    Recruiting
    • Michael Priv.Doz. Dr.med.univ. Leutner, PhD MSc · ContactMichael.Leutner@meduniwien.ac.at · +43 1 404 00-60950
    • Ricarda Rosalia Baron, MSc, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 12 months is below that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
Jul 6, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07685015
Collaborators
BIOGENA GmbH, Salzburg
Responsible party
Michael Leutner (Priv.Doz. Dr.med.univ., Medical University of Vienna) — Principal investigator
First posted
Jul 6, 2026
Start date
Mar 23, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Michael Priv.Doz. Dr.med.univ. Leutner, PhD MSc
Contact
michael.leutner@meduniwien.ac.at
+43 1 404 00-60950
Ricarda Rosalia Baron, MSc, Msc
Contact
Ricarda.Baron@meduniwien.ac.at
+43 1 404 00-20690

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inositol

Start the discussion